Actively Recruiting

Age: 18Years +
All Genders
ID06006832

Clinical Characteristics, Prognosis and Biomarkers of Myasthenia Gravis: a Prospective Cohort Study in China

Led by Peking Union Medical College Hospital · Updated on 2024-01-12

202

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating long-term treatment strategies and biomarkers for myasthenia gravis (MG) in this prospective cohort study. The study focuses on whether maintaining low-dose oral steroids can reduce the recurrence rate of MG and aims to identify biomarkers that may predict disease progression and prognosis. Participants are patients with well-controlled MG. Participants are divided into two groups based on their preferences and medical considerations such as other health conditions. One group continues low-dose oral steroid therapy while the other group withdraws from all immunosuppressants. These groups will be monitored over a long-term period with regular assessments. During the study, participants will undergo follow-up evaluations to monitor MG relapses within two years after recruitment. Researchers will assess the timing of relapses, changes in MG assessment scales, and any adverse events related to steroid use. This ongoing monitoring aims to better understand treatment outcomes and disease progression in MG patients.

CONDITIONS

Brief Title

A Prospective Cohort Study of Myasthenia Gravis in China

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Attended the outpatient department of neurology of PUMCH from 9/30/2022 to 9/30/2024
  • Diagnosed with myasthenia gravis
  • Follow-up time at PUMCH longer than 6 months
  • Patient understood and signed the informed consent form
Not Eligible

You will not qualify if you...

  • Other conditions causing skeletal muscle weakness that make symptoms hard to assess
  • Missing records for comorbidities or medications at baseline or during follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - Up to 2 years

Participants are observed for relapse and changes in their condition while maintaining low-dose oral steroids or after withdrawing immunosuppressants.

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

Y

Yuzhou Guan

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Non-interventional, Post-authorisation Safety Study of Pat...

Myasthenia Gravis

Actively Recruiting

35 locations

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatme...

Muscular Diseases

Actively Recruiting

13 locations

A Phase 1b/2 Study of IM-101 to Evaluate Safety, Tolerabilit...

Myasthenia Gravis

Actively Recruiting

25 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here